Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

WuXi AppTec

Founders Ge Li John J. Baldwin Zhaohui Zhang

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 46
Average round size
info
The average size of a deal this fund participated in
$54M
Portfolio companies 36
Rounds per year 1.92
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.22
Exits 7
Key employees 2

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Medical
  • Artificial Intelligence
Summary

WuXi AppTec appeared to be the Corporate Investor, which was created in 2000. The main department of described Corporate Investor is located in the Shanghai. The venture was found in Asia in China.

Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Hua Medicine, DNAnexus, Schrodinger. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Health Care, Real Time.

The fund was created by Ge Li, John J. Baldwin, Zhaohui Zhang. The overall number of key employees were 2.

Opposing the other organizations, this WuXi AppTec works on 20 percentage points less the average amount of lead investments. The increased amount of exits for fund were in 2018. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 2-6 deals every year. Considering the real fund results, this Corporate Investor is 2 percentage points less often commits exit comparing to other organizations.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the WuXi AppTec, startups are often financed by Venrock, WuXi Healthcare Ventures, First Round Capital. The meaningful sponsors for the fund in investment in the same round are ARCH Venture Partners, Sequoia Capital China, Watson Fund. In the next rounds fund is usually obtained by Invus, WuXi NextCODE, WuXi Healthcare Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of WuXi AppTec:
Typical Co-investors
WuXi AppTec is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after WuXi AppTec:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AlphaCoin Fund Boston, Massachusetts, United States
Asahi Medialab Ventures Chiyoda, Japan
Bet Haemek -
CDC IXIS Innovation France, Ile-de-France, Paris
Enza Capital Kenya, Nairobi, Nairobi Area
Goff Capital Fort Worth, Texas, United States
Hotbit China, Shanghai
Huigu Chuang Tou Changning, China, Shanghai
Innogenetics Belgium, Gent, Oost-Vlaanderen
Kodak New York, Rochester, United States
Natco Pharma Andhra Pradesh, Hyderabad, India
Red Hat North Carolina, Raleigh, United States
Sesame Street Alabama, America, United States
Shigin Economic Research Institute -
Software Holding & Finance Belgium, Flemish Brabant, Vlaams-Brabant
Starstrike Ventures Berlin, Berlin, Germany
Telegraph Hill Capital California, San Francisco, United States
Treasury New York, New York, United States
Upfront Ventures Community Fund California, Los Angeles, United States
Yidou Investment China, Guangdong, Shenzhen

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

D3 Bio

Biotechnology
Life Science
Pharmaceutical
$62M08 Apr 2024 Shanghai, China

Bioyond Tech

Artificial Intelligence
Medical Device
Robotics
$30M03 Apr 2023 Pudong, Shandong, China

ShouTi

Biotechnology
Health Care
Medical
Pharmaceutical
Product Research
$100M20 Oct 2021 Shanghai, China

Stemirna

Biotechnology
Medical
Pharmaceutical
$185M03 Jun 2021 Dongcheng District, Beijing, China

Engine Biosciences

Artificial Intelligence
Biotechnology
Health Care
Machine Learning
$43M26 May 2021 San Francisco, California, United States

OakMega

CRM
Information Technology
Internet
10 May 2021 New Taipei, Taiwan

AnchorDx

Biotechnology
Emergency Medicine
Pharmaceutical
$40M22 Feb 2021 Guangdong Province

Biotechnology
$56M09 Feb 2021 Shanghai, China

Biotechnology
Life Science
Pharmaceutical
$200M17 Nov 2020 Shanghai, China
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics

– Engine Biosciences announced the successful completion of an oversubscribed $43m Series A funding round.
– Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.
– This round was led by Polaris Partners and also included new investors Invus and one of the world’s premier institutional investors, based in Singapore.
– Existing investors also participated in the Series A, which included 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio.
– Amy Schulman, Managing Partner at Polaris Partners, has joined the Engine Biosciences Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent WuXi AppTec?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 46
Average round size 54M
Rounds per year 1.92
Peak activity year 2021
Lead investments 7
Follow on index 0.22
Exits 7
Group Appearance index 0.98

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

D3 Bio

Biotechnology
Life Science
Pharmaceutical
$62M08 Apr 2024 Shanghai, China

Bioyond Tech

Artificial Intelligence
Medical Device
Robotics
$30M03 Apr 2023 Pudong, Shandong, China

ShouTi

Biotechnology
Health Care
Medical
Pharmaceutical
Product Research
$100M20 Oct 2021 Shanghai, China

Stemirna

Biotechnology
Medical
Pharmaceutical
$185M03 Jun 2021 Dongcheng District, Beijing, China

Engine Biosciences

Artificial Intelligence
Biotechnology
Health Care
Machine Learning
$43M26 May 2021 San Francisco, California, United States

OakMega

CRM
Information Technology
Internet
10 May 2021 New Taipei, Taiwan

AnchorDx

Biotechnology
Emergency Medicine
Pharmaceutical
$40M22 Feb 2021 Guangdong Province

Biotechnology
$56M09 Feb 2021 Shanghai, China

Biotechnology
Life Science
Pharmaceutical
$200M17 Nov 2020 Shanghai, China
Crunchbase icon

Content report

The following text will be sent to our editors: